Matches in SemOpenAlex for { <https://semopenalex.org/work/W3176942856> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W3176942856 endingPage "P" @default.
- W3176942856 startingPage "792" @default.
- W3176942856 abstract "In the EMPA-REG OUTCOME trial empagliflozin (EMPA) reduced the risk of cardiovascular death, all-cause mortality, and hospitalization for heart failure in patients with type 2 diabetes (T2D) and established cardiovascular disease. The comparative safety of EMPA in routine care is yet to be established. EMPRISE studies the effectiveness, safety and healthcare utilization of EMPA, based on data from Medicare and 2 U.S. commercial claims datasets (2014-2019). In an interim analysis using data from 2014-2018 (2014-2017 in Medicare), we identified 55,580 pairs of 1:1 propensity score-matched patients ≥18 years with T2D initiating EMPA or a DPP4 inhibitor (DPP4i). Safety outcomes of interest included lower-limb amputations (LLA), bone fractures, diabetic ketoacidosis hospitalization (DKA), and acute kidney injury hospitalization (AKI). We estimated pooled HR and RD/1000 PY with their 95% CI adjusting for >140 baseline covariates. Over a mean follow up of 6.3 months, EMPA initiators had similar risk of LLA and fractures, an increased risk of DKA [HR, 2.01 (1.37-2.95); RD, 1.44 (0.72,2.17) per 1000 PY], and a decreased risk of AKI [HR, 0.66 (0.59-0.74); RD, -8.59 (-10.93,-6.25) per 1000 PY], compared with DPP4i (Table). In routine care, the initiation of EMPA was associated with a safety profile in line with documented information.View largeDownload slideView largeDownload slide DisclosureE. Patorno: Research Support; Self; Boehringer Ingelheim International GmbH, National Institutes of Health. S. Schneeweiss: Other Relationship; Self; Aetion. H. Tesfaye: None. D. J. Wexler: Board Member; Self; Novo Nordisk. R. Glynn: Research Support; Self; AstraZeneca, Kowa Research Institute, Inc., Novartis AG, Pfizer Inc. M. Najafzadeh: None. L. G. Bessette: Consultant; Self; Aetion, Inc. H. Zakoul: None. L. Koeneman: Employee; Self; Eli Lilly and Company, Stock/Shareholder; Self; Eli Lilly and Company. A. Deruaz-luyet: Employee; Self; Boehringer Ingelheim (Canada) Ltd., Employee; Spouse/Partner; Sanofi-Aventis Deutschland GmbH." @default.
- W3176942856 created "2021-07-05" @default.
- W3176942856 creator A5004416630 @default.
- W3176942856 creator A5030822229 @default.
- W3176942856 creator A5037108542 @default.
- W3176942856 creator A5037322697 @default.
- W3176942856 creator A5044094148 @default.
- W3176942856 creator A5044474781 @default.
- W3176942856 creator A5045723863 @default.
- W3176942856 creator A5047891240 @default.
- W3176942856 creator A5074777366 @default.
- W3176942856 creator A5076997901 @default.
- W3176942856 date "2021-06-01" @default.
- W3176942856 modified "2023-09-23" @default.
- W3176942856 title "792-P: Comparative Safety of Empagliflozin in Routine Care Patients: Interim Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study" @default.
- W3176942856 doi "https://doi.org/10.2337/db21-792-p" @default.
- W3176942856 hasPublicationYear "2021" @default.
- W3176942856 type Work @default.
- W3176942856 sameAs 3176942856 @default.
- W3176942856 citedByCount "0" @default.
- W3176942856 crossrefType "journal-article" @default.
- W3176942856 hasAuthorship W3176942856A5004416630 @default.
- W3176942856 hasAuthorship W3176942856A5030822229 @default.
- W3176942856 hasAuthorship W3176942856A5037108542 @default.
- W3176942856 hasAuthorship W3176942856A5037322697 @default.
- W3176942856 hasAuthorship W3176942856A5044094148 @default.
- W3176942856 hasAuthorship W3176942856A5044474781 @default.
- W3176942856 hasAuthorship W3176942856A5045723863 @default.
- W3176942856 hasAuthorship W3176942856A5047891240 @default.
- W3176942856 hasAuthorship W3176942856A5074777366 @default.
- W3176942856 hasAuthorship W3176942856A5076997901 @default.
- W3176942856 hasConcept C126322002 @default.
- W3176942856 hasConcept C134018914 @default.
- W3176942856 hasConcept C138411078 @default.
- W3176942856 hasConcept C166957645 @default.
- W3176942856 hasConcept C185592680 @default.
- W3176942856 hasConcept C199289684 @default.
- W3176942856 hasConcept C2775887513 @default.
- W3176942856 hasConcept C2776957806 @default.
- W3176942856 hasConcept C2777180221 @default.
- W3176942856 hasConcept C2779306644 @default.
- W3176942856 hasConcept C2780652884 @default.
- W3176942856 hasConcept C2781283889 @default.
- W3176942856 hasConcept C2781308992 @default.
- W3176942856 hasConcept C555293320 @default.
- W3176942856 hasConcept C71924100 @default.
- W3176942856 hasConcept C95457728 @default.
- W3176942856 hasConceptScore W3176942856C126322002 @default.
- W3176942856 hasConceptScore W3176942856C134018914 @default.
- W3176942856 hasConceptScore W3176942856C138411078 @default.
- W3176942856 hasConceptScore W3176942856C166957645 @default.
- W3176942856 hasConceptScore W3176942856C185592680 @default.
- W3176942856 hasConceptScore W3176942856C199289684 @default.
- W3176942856 hasConceptScore W3176942856C2775887513 @default.
- W3176942856 hasConceptScore W3176942856C2776957806 @default.
- W3176942856 hasConceptScore W3176942856C2777180221 @default.
- W3176942856 hasConceptScore W3176942856C2779306644 @default.
- W3176942856 hasConceptScore W3176942856C2780652884 @default.
- W3176942856 hasConceptScore W3176942856C2781283889 @default.
- W3176942856 hasConceptScore W3176942856C2781308992 @default.
- W3176942856 hasConceptScore W3176942856C555293320 @default.
- W3176942856 hasConceptScore W3176942856C71924100 @default.
- W3176942856 hasConceptScore W3176942856C95457728 @default.
- W3176942856 hasIssue "Supplement 1" @default.
- W3176942856 hasLocation W31769428561 @default.
- W3176942856 hasOpenAccess W3176942856 @default.
- W3176942856 hasPrimaryLocation W31769428561 @default.
- W3176942856 hasRelatedWork W2345837623 @default.
- W3176942856 hasRelatedWork W2588682962 @default.
- W3176942856 hasRelatedWork W2900336056 @default.
- W3176942856 hasRelatedWork W2955140044 @default.
- W3176942856 hasRelatedWork W3034642746 @default.
- W3176942856 hasRelatedWork W3152910579 @default.
- W3176942856 hasRelatedWork W4200008162 @default.
- W3176942856 hasRelatedWork W4200216240 @default.
- W3176942856 hasRelatedWork W4200619784 @default.
- W3176942856 hasRelatedWork W4281768514 @default.
- W3176942856 hasVolume "70" @default.
- W3176942856 isParatext "false" @default.
- W3176942856 isRetracted "false" @default.
- W3176942856 magId "3176942856" @default.
- W3176942856 workType "article" @default.